Idiopathic Pulmonary Fibrosis: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797403
  • Drug Pipelines
  • 192 pages
  • Datamonitor Healthcare
1 of 3
The FDA simultaneously approved both Esbriet and Ofev in October 2014, making them the first treatments specifically approved for IPF in the US.

This report addresses the following questions:

- How large is the IPF patient population and how many patients are drug-treated across the various severities?
- What clinical differentiation exists between the two approved products and how does this sway physician behavior?
- What degree of uptake are Esbriet and Ofev experiencing shortly after their launch?
- How will the sales trajectories of the two products differ?
- Now that there are specifically approved treatment options, how will clinical trial design and product positioning for future products change?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: IDIOPATHIC PULMONARY FIBROSIS

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Esbriet (pirfenidone)
- Ofev (nintedanib)
- Primary Research Methodology

TREATMENT: IDIOPATHIC PULMONARY FIBROSIS

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis,
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends

EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS

- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: IDIOPATHIC PULMONARY FIBROSIS

- Executive Summary
- Product Overview
- Product profile: Esbriet
- Product profile: Ofev

PIPELINE: IDIOPATHIC PULMONARY FIBROSIS

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Clinical Trial Design
- Product profile (late stage): FG-30
- Product profile (late stage): PRM-151
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll